Trials / Recruiting
RecruitingNCT05767047
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 5 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apremilast | Oral tablets or liquid suspension |
Timeline
- Start date
- 2023-03-23
- Primary completion
- 2036-03-17
- Completion
- 2036-03-17
- First posted
- 2023-03-14
- Last updated
- 2025-12-01
Locations
7 sites across 4 countries: Greece, Israel, Spain, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05767047. Inclusion in this directory is not an endorsement.